The analysis evaluating the effect of the TFAP2A gene expression at the time of diagnosis on the survival time of NSCLC patients (Figure 8A) revealed that higher expression correlated with a shorter five years OS (p < 0.001) for overall lung cancer (LC) and after division to LUAD (p = 0.029) and LUSC (p = 0.034) subtypes. Here, TFAP2A is linked to lung cancer.